{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:24:54Z","timestamp":1787775894569,"version":"build-2784847793"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","award":["ACL program"],"award-info":[{"award-number":["ACL program"]}],"id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000761","name":"Imperial College London","doi-asserted-by":"publisher","award":["ACL program"],"award-info":[{"award-number":["ACL program"]}],"id":[{"id":"10.13039\/501100000761","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"DH | National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lymph&Co - the registered charity in Amsterdam to fund lymphoma research."},{"name":"Lymph&Co - the registered charity in Amsterdam to fund lymphoma research."},{"name":"Lymph&Co - the registered charity in Amsterdam to fund lymphoma research."},{"name":"Lymph&Co - the registered charity in Amsterdam to fund lymphoma research."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-00999-8","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T08:02:05Z","timestamp":1707811325000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8476-9623","authenticated-orcid":false,"given":"Danmei","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-7965","authenticated-orcid":false,"given":"Findlay","family":"Bewicke-Copley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Close","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6021-5044","authenticated-orcid":false,"given":"Jessica","family":"Okosun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1710-1794","authenticated-orcid":false,"given":"Jane","family":"Apperley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8724-3907","authenticated-orcid":false,"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-4670","authenticated-orcid":false,"given":"Hans-Guido","family":"Wendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9069-1866","authenticated-orcid":false,"given":"Jude","family":"Fitzgibbon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"999_CR1","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1182\/blood.2021013326","volume":"139","author":"TA Eyre","year":"2022","unstructured":"Eyre TA, Cheah CY, Wang ML. Therapeutic options for relapsed\/refractory mantle cell lymphoma. Blood. 2022;139:666\u201377.","journal-title":"Blood"},{"key":"999_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/blood.2020005289","volume":"136","author":"F Nadeu","year":"2020","unstructured":"Nadeu F, Martin-Garcia D, Clot G, Diaz-Navarro A, Duran-Ferrer M, Navarro A, et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020;136:1419\u201332.","journal-title":"Blood"},{"key":"999_CR3","doi-asserted-by":"publisher","first-page":"e153283","DOI":"10.1172\/JCI153283","volume":"132","author":"S Yi","year":"2022","unstructured":"Yi S, Yan Y, Jin M, Bhattacharya S, Wang Y, Wu Y, et al. Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. J Clin Investig. 2022;132:e153283.","journal-title":"J Clin Investig"},{"key":"999_CR4","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1056\/NEJMra1805035","volume":"383","author":"SE Bates","year":"2020","unstructured":"Bates SE. Epigenetic therapies for cancer. N Engl J Med. 2020;383:650\u201363.","journal-title":"N Engl J Med"},{"key":"999_CR5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.25796","volume":"95","author":"S Zhao","year":"2020","unstructured":"Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL)\u2014outcomes and mutation profile from venetoclax resistant MCL patients. Am J Haematol. 2020;95:623\u20139.","journal-title":"Am J Haematol"},{"key":"999_CR6","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.3324\/haematol.2018.214056","volume":"105","author":"S Ferrero","year":"2020","unstructured":"Ferrero S, Rossi D, Rinaldi A, Bruscaggin A, Spina V, Eskelund CW, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. Haematologica. 2020;105:1604\u201312.","journal-title":"Haematologica"},{"key":"999_CR7","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.18632\/oncotarget.27988","volume":"12","author":"SS Dhar","year":"2021","unstructured":"Dhar SS, Lee MG. Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors. Oncotarget. 2021;12:1296\u2013308.","journal-title":"Oncotarget"},{"key":"999_CR8","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/nm.3940","volume":"21","author":"J Zhang","year":"2015","unstructured":"Zhang J, Dominguez-Sola D, Hussein S, Lee JE, Holmes AB, Bansal M, et al. Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis. Nat Med. 2015;21:1190\u20138.","journal-title":"Nat Med"},{"key":"999_CR9","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/nm.3943","volume":"21","author":"A Ortega-Molina","year":"2015","unstructured":"Ortega-Molina A, Boss IW, Canela A, Pan H, Jiang Y, Zhao C, et al. The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nat Med. 2015;21:1199\u2013208.","journal-title":"Nat Med"},{"key":"999_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/blood.2020008743","volume":"138","author":"JA Heward","year":"2021","unstructured":"Heward JA, Konali L, D\u2019Avola A, Close K, Yeomans A, Philpott M, et al. KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood. 2021;138:370\u201381.","journal-title":"Blood"},{"key":"999_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1182\/blood.2021011647","volume":"138","author":"E Oricchio","year":"2021","unstructured":"Oricchio E. Epigenetic balance in DLBCL. Blood. 2021;138:355\u20136.","journal-title":"Blood"},{"key":"999_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69\u201380.","journal-title":"Cell"},{"key":"999_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2643-3230.BCD-20-0108","volume":"2","author":"H Ohguchi","year":"2021","unstructured":"Ohguchi H, Park PMC, Wang T, Gryder BE, Ogiya D, Kurata K, et al. Lysine Demethylase 5A is required for MYC driven transcription in multiple myeloma. Blood Cancer Discov. 2021;2:370\u201387.","journal-title":"Blood Cancer Discov"},{"key":"999_CR14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3324\/haematol.2020.274258","volume":"107","author":"M Ma","year":"2022","unstructured":"Ma M, Tadros S, Bouska A, Heavican T, Yang H, Deng Q, et al. Subtype-specific and co-occurring genetic alterations in B-cell non-Hodgkin lymphoma. Haematologica. 2022;107:690\u2013701.","journal-title":"Haematologica"},{"key":"999_CR15","first-page":"1","volume":"12","author":"G Paroni","year":"2018","unstructured":"Paroni G, Bolis M, Zanetti A, Ubezio P, Helin K, Staller P, et al. HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases. Oncogene. 2018;12:1\u20132689.","journal-title":"Oncogene"},{"key":"999_CR16","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1182\/blood-2016-04-711176","volume":"128","author":"C Jacobson","year":"2016","unstructured":"Jacobson C, Kopp N, Layer JV, Redd RA, Tschuri S, Haebe S, et al. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood. 2016;128:2517\u201326.","journal-title":"Blood"},{"key":"999_CR17","doi-asserted-by":"publisher","first-page":"e410","DOI":"10.3324\/haematol.2018.212811","volume":"104","author":"T D\u2019Agaro","year":"2019","unstructured":"D\u2019Agaro T, Zucchetto A, Vit F, Bittolo T, Tissino E, Rossi FM, et al. A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. Haematologica. 2019;104:e410\u201314.","journal-title":"Haematologica"},{"key":"999_CR18","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1182\/bloodadvances.2018016048","volume":"2","author":"J Lee","year":"2018","unstructured":"Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, et al. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018;2:2039\u201351.","journal-title":"Blood Adv"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00999-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00999-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00999-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T08:02:18Z","timestamp":1707811338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-00999-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["999"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-00999-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,13]]},"assertion":[{"value":"16 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GS716054 is a pro-drug developed by Gilead Science Inc. MTA was signed between Gilead and Queen Mary University of London (QMUL) where JF was the principal investigator. JF is now an employee of AstraZeneca Inc. DMW, now an employee of Merck and Co., owns equity in Merck and Co., Bantam, Ajax, and Travera, received consulting fees from Astra Zeneca, Secura, Novartis, and Roche\/Genentech, and received research support from Daiichi Sankyo, Astra Zeneca, Verastem, Abbvie, Novartis, Abcura, and Surface Oncology. RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}